Skip to content
MarketScale
‹ Back to IndustriesSciences

SupplySide West 2021: CEO Insights

Deerland Probiotics and Enzymes, led by CEO Scott Ravitch, is thrilled to be back at Supply Side West in Las Vegas. This prestigious trade show is a crucial event for the company, providing an opportunity to reconnect with important customers, prospective clients, suppliers, and industry professionals. With a focus on branded clinical products, Deerland…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · DeerlandEnzymesProbioticSupplyside West
Share

Key takeaways

01

Deerland Probiotics and Enzymes, led by CEO Scott Ravitch, is thrilled to be back at Supply Side West in Las Vegas.

02

This prestigious trade show is a crucial event for the company, providing an opportunity to reconnect with important customers, prospective clients, suppliers, and industry professionals.

03

With a focus on branded clinical products, Deerland…

Deerland Probiotics and Enzymes, led by CEO Scott Ravitch, is thrilled to be back at Supply Side West in Las Vegas. This prestigious trade show is a crucial event for the company, providing an opportunity to reconnect with important customers, prospective clients, suppliers, and industry professionals. With a focus on branded clinical products, Deerland Probiotics and Enzymes is showcasing innovative solutions that make a measurable difference in people’s lives.

One of the standout products is Pre4 Pro, a unique prebiotic that works effectively in small quantities, just 15 milligrams. Unlike mainstream prebiotics, Pre4 Pro doesn’t cause digestive discomfort. Additionally, the flagship DE111 probiotic offers tremendous benefits for digestive well-being and immunity. This versatile probiotic finds applications in various forms, from traditional supplements like capsules and tablets to more exciting options such as gummies, kombuchas, and food and beverage products. Another highlight is Solarplast, a potent antioxidant product that contributes to beauty from within. All these offerings are backed by robust human clinical studies, a testament to Deerland’s commitment to science and substantiated claims.

Over the past two years, Deerland Probiotics and Enzymes has made remarkable progress despite the challenges posed by the COVID-19 pandemic. The company has focused on conducting clinical studies and expanding its product portfolio. With six completed studies, including a groundbreaking germination study for DE111, Deerland has solid scientific evidence to support its offerings. They have also continued new product development, introducing Munispor for immune health and having three more products in the pipeline for launch. The integration of the Bifidin acquisition in 2019 has further enriched Deerland’s capabilities.

Looking ahead to 2021 and beyond, Deerland Probiotics and Enzymes remains committed to providing competitive differentiation and delivering exceptional value to its customers. By offering consultative solutions, the company goes beyond being an ingredients or manufacturing provider. Their team takes the time to understand customers’ goals and consumer needs, co-creating the best formulations for their products. This customer-centric approach has enabled Deerland’s partners to launch successful brands and attract new customers. The company’s culture, rooted in core values and a mission to make a measurable difference in people’s lives, serves as a guiding force in every decision and action.

Deerland Probiotics and Enzymes is dedicated to advancing science, expanding their portfolio, and building strong partnerships. With an unwavering commitment to quality, performance, and safety, they create innovative solutions that address emerging market needs. The company is grateful for the trust and faith that customers place in them and takes pride in the positive impact their products and services have on people’s lives.

Join Deerland Probiotics and Enzymes on their mission to make a measurable difference in the quality of people’s lives. Experience their scientific expertise, consultative approach, and commitment to excellence.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512